Deregulation of an imprinted gene network in prostate cancer

Epigenetics

Volumn 9, Issue 5, 2014, Pages 704-717

  Ribarska, Teodora ^a   Goering, Wolfgang ^a   Droop, Johanna ^a   Bastian, Klaus Marius ^a   Ingenwerth, Marc ^a   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cancer epigenetics; Differentially methylated region; DNA methylation; Imprinted gene network; Imprinted genes; Prostate cancer; Pyrosequencing; ZAC1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARYLDIALKYLPHOSPHATASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1C; GENOMIC DNA; HOXC6; LONG QT INTRONIC TRANSCRIPT 1; MATERNALLY EXPRESSED GENE 3; NECDIN; PEIOMORPHIC ADENOMA GENE LIKE 1; PHOSPHOPROTEIN PHOSPHATASE; POLYCOMB REPRESSIVE COMPLEX 2; PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY; PROTEIN PHOSPHATASE 1 REGULATORY SUBUNIT 9A; RNA H19; SOMATOMEDIN B; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VORINOSTAT; ZAC1; ACTIN BINDING PROTEIN; ANDROGEN; CELL CYCLE PROTEIN; ERG PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; HOXC6 PROTEIN, HUMAN; NERVE PROTEIN; NEURABIN; PLAGL1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DEREGULATION; DNA EXTRACTION; DNA METHYLATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REGULATORY NETWORK; GENOME IMPRINTING; GLEASON SCORE; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; GENETIC EPIGENESIS; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; GENE REGULATORY NETWORKS; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICROFILAMENT PROTEINS; NERVE TISSUE PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; PROSTATE; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84899840037     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.28006     Document Type: Article

References (65)

1. Arima T, Kamikihara T, Hayashida T, Kato K, Inoue T, Shirayoshi Y, Oshimura M, Soejima H, Mukai T, Wake N. ZAC, LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome. Nucleic Acids Res 2005; 33:2650-60; PMID:15888726; http://dx.doi.org/10.1093/nar/gki555
2. Dekel B, Metsuyanim S, Schmidt-Ott KM, Fridman E, Jacob-Hirsch J, Simon A, Pinthus J, Mor Y, Barasch J, Amariglio N, et al. Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. Cancer Res 2006; 66:6040-9; PMID:16778176; http://dx.doi.org/10.1158/0008-5472.CAN-05-4528
3. Jacob KJ, Robinson WP, Lefebvre L. Beckwith- Wiedemann and Silver-Russell syndromes: opposite developmental imbalances in imprinted regulators of placental function and embryonic growth. Clin Genet 2013; 84:326-34; PMID:23495910; http://dx.doi.org/10.1111/cge.12143
4. Jelinic P, Shaw P. Loss of imprinting and cancer. J Pathol 2007; 211:261-8; PMID:17177177; http://dx.doi.org/10.1002/path.2116
5. Uribe-Lewis S, Woodfine K, Stojic L, Murrell A. Molecular mechanisms of genomic imprinting and clinical implications for cancer. Expert Rev Mol Med 2011; 13:e2; PMID:21262060; http://dx.doi.org/10.1017/S1462399410001717
6. Murrell A. Genomic imprinting and cancer: from primordial germ cells to somatic cells. ScientificWorldJournal 2006; 6:1888-910; PMID:17205195; http://dx.doi.org/10.1100/tsw.2006.318
7. Zuo QS, Yan R, Feng DX, Zhao R, Chen C, Jiang YM, Cruz-Correa M, Casson AG, Kang XD, Han F, et al. Loss of imprinting and abnormal expression of the insulin-like growth factor 2 gene in gastric cancer. Mol Carcinog 2011; 50:390-6; PMID:21268128; http://dx.doi.org/10.1002/mc.20731
8. Ito Y, Koessler T, Ibrahim AE, Rai S, Vowler SL, Abu- Amero S, Silva AL, Maia AT, Huddleston JE, Uribe- Lewis S, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet 2008; 17:2633-43; PMID:18541649; http://dx.doi.org/10.1093/hmg/ddn163
9. Cui H. Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers 2007; 23:105-12; PMID:17325430; http://dx.doi.org/10.1155/2007/363464
10. Ferguson-Smith AC. Genomic imprinting: the emergence of an epigenetic paradigm. Nat Rev Genet 2011; 12:565-75; PMID:21765458; http://dx.doi.org/10.1038/nrg3032
11. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60:753-766; PMID:21719191; http://dx.doi.org/10.1016/j.eururo.2011.06.035
12. Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 2007; 12:4254-66; PMID:17485372; http://dx.doi.org/10.2741/2385
13. Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate 2011; 71:1621-30; PMID:21432864; http://dx.doi.org/10.1002/pros.21379
14. Ribarska T, Bastian KM, Koch A, Schulz WA. Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation. Asian J Androl 2012; 14:436-50; PMID:22367183; http://dx.doi.org/10.1038/aja.2011.160
15. Varrault A, Gueydan C, Delalbre A, Bellmann A, Houssami S, Aknin C, Severac D, Chotard L, Kahli M, Le Digarcher A, et al. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev Cell 2006; 11:711-722; PMID:17084362; http://dx.doi.org/10.1016/j.devcel.2006.09.003
16. Gabory A, Ripoche MA, Le Digarcher A, Watrin F, Ziyyat A, Forné T, Jammes H, Ainscough JF, Surani MA, Journot L, et al. H19 acts as a trans regulator of the imprinted gene network controlling growth in mice. Development 2009; 136:3413-21; PMID:19762426; http://dx.doi.org/10.1242/dev.036061
17. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9; PMID:12374981; http://dx.doi.org/10.1038/nature01075
18. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-8; PMID:16254181; http://dx.doi.org/10.1126/science.1117679
19. Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS, Nordeen SK. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res 2003; 63:5879-88; PMID:14522913
20. McCabe CD, Spyropoulos DD, Martin D, Moreno CS. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res 2008; 68:1988-96; PMID:18339881; http://dx.doi.org/10.1158/0008-5472.CAN-07-5843
21. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012; 338:1465-1469; PMID:23239736; http://dx.doi.org/10.1126/science.1227604
22. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18:11-22; PMID:20579941; http://dx.doi.org/10.1016/j.ccr.2010.05.026
23. Ribarska T, Ingenwerth M, Goering W, Engers R, Schulz WA. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genomics Proteomics 2010; 7:51-60; PMID:20335518
24. Choi JD, Underkoffler LA, Wood AJ, Collins JN, Williams PT, Golden JA, Schuster EF Jr., Loomes KM, Oakey RJ.A novel variant of Inpp5f is imprinted in brain, and its expression is correlated with differential methylation of an internal CpG island. Mol Cell Biol 2005; 25:5514-22; PMID:15964807; http://dx.doi.org/10.1128/MCB.25.13.5514-5522.2005
25. Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006; 66:1521-1534; PMID:16921506; http://dx.doi.org/10.1002/pros.20490
26. Wilkin F, Paquette J, Ledru E, Hamelin C, Pollak M, Deal CL. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Eur J Biochem 2000; 267:4020-7; PMID:10866801; http://dx.doi.org/10.1046/j.1432-1327.2000.01438.x
27. Hoffmann MJ, Florl AR, Seifert HH, Schulz WA. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 2005; 114:406-13; PMID:15551363; http://dx.doi.org/10.1002/ijc.20749
28. Fitzpatrick GV, Soloway PD, Higgins MJ.Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1. Nat Genet 2002; 32:426-31; PMID:12410230; http://dx.doi.org/10.1038/ng988
29. Vinarskaja A, Yamanaka M, Ingenwerth M, Schulz WA. DNA Methylation and the HOXC6 Paradox in Prostate Cancer. Cancers (Basel) 2011; 3:3714-725; PMID:24213107; http://dx.doi.org/10.3390/cancers3043714
30. Bourque DK, Avila L, Peñaherrera M, von Dadelszen P, Robinson WP. Decreased placental methylation at the H19/IGF2 imprinting control region is associated with normotensive intrauterine growth restriction but not preeclampsia. Placenta 2010; 31:197-202; PMID:20060582; http://dx.doi.org/10.1016/j.placenta.2009.12.003
31. Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T, Nikolaidis G, Sigala F, Kittas C, Field JK, et al. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 2006; 119:2546-56; PMID:16988944; http://dx.doi.org/10.1002/ijc.22214
32. Monk D, Wagschal A, Arnaud P, Müller PS, Parker-Katiraee L, Bourc'his D, Scherer SW, Feil R, Stanier P, Moore GE. Comparative analysis of human chromosome 7q21 and mouse proximal chromosome 6 reveals a placental-specific imprinted gene, TFPI2/Tfpi2, which requires EHMT2 and EED for allelic-silencing. Genome Res 2008; 18:1270-1281; PMID:18480470; http://dx.doi.org/10.1101/gr.077115.108
33. Nakabayashi K, Makino S, Minagawa S, Smith AC, Bamforth JS, Stanier P, Preece M, Parker-Katiraee L, Paton T, Oshimura M, et al. Genomic imprinting of PPP1R9A encoding neurabin I in skeletal muscle and extra-embryonic tissues. J Med Genet 2004; 41:601-8; PMID:15286155; http://dx.doi.org/10.1136/jmg.2003.014142
34. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 2007; 6:1403-12; PMID:18637271; http://dx.doi.org/10.4161/cbt.6.9.4542
35. Schulz WA, Ingenwerth M, Djuidje CE, Hader C, Rahnenführer J, Engers R. Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation. BMC Cancer 2010; 10:505; PMID:20860828; http://dx.doi.org/10.1186/1471-2407-10-505
36. Smits G, Kelsey G. Imprinting weaves its web. Dev Cell 2006; 11:598-9; PMID:17084353; http://dx.doi.org/10.1016/j.devcel.2006.10.013
37. Sandhu KS, Shi C, Sjölinder M, Zhao Z, Göndör A, Liu L, Tiwari VK, Guibert S, Emilsson L, Imreh MP, et al. Nonallelic transvection of multiple imprinted loci is organized by the H19 imprinting control region during germline development. Genes Dev 2009; 23:2598-603; PMID:19933149; http://dx.doi.org/10.1101/gad.552109
38. Berg JS, Lin KK, Sonnet C, Boles NC, Weksberg DC, Nguyen H, Holt LJ, Rickwood D, Daly RJ, Goodell MA. Imprinted genes that regulate early mammalian growth are coexpressed in somatic stem cells. PLoS One 2011; 6:e26410; PMID:22039481; http://dx.doi.org/10.1371/journal.pone.0026410
39. Lui JC, Finkielstain GP, Barnes KM, Baron J.An imprinted gene network that controls mammalian somatic growth is down-regulated during postnatal growth deceleration in multiple organs. Am J Physiol Regul Integr Comp Physiol 2008; 295:R189-R196; PMID:18448610; http://dx.doi.org/10.1152/ajpregu.00182.2008
40. Zhao Z, Tavoosidana G, Sjölinder M, Göndör A, Mariano P, Wang S, Kanduri C, Lezcano M, Sandhu KS, Singh U, et al. Circular chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra- and interchromosomal interactions. Nat Genet 2006; 38:1341-7; PMID:17033624; http://dx.doi.org/10.1038/ng1891
41. Liu W, Chang BL, Cramer S, Koty PP, Li T, Sun J, Turner AR, Von Kap-Herr C, Bobby P, Rao J, et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res 2007; 13:5028-33; PMID:17785553; http://dx.doi.org/10.1158/1078-0432.CCR-07-0300
42. Bachmann N, Haeusler J, Luedeke M, Kuefer R, Perner S, Assum G, Paiss T, Hoegel J, Vogel W, Maier C. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet Cytogenet 2008; 182:103-10; PMID:18406871; http://dx.doi.org/10.1016/j.cancergencyto.2008.01.006
43. Florl AR, Steinhoff C, Müller M, Seifert HH, Hader C, Engers R, Ackermann R, Schulz WA. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004; 91:985-94; PMID:15292941
44. Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Müller M, Lengauer T, et al. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 2007; 6:14; PMID:17280610; http://dx.doi.org/10.1186/1476-4598-6-14
45. Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G, Yang AS. Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res 2007; 67:10753-8; PMID:18006818; http://dx.doi.org/10.1158/0008-5472.CAN-07-0329
46. Paradowska A, Fenic I, Konrad L, Sturm K, Wagenlehner F, Weidner W, Steger K. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia. Int J Oncol 2009; 35:87-96; PMID:19513555; http://dx.doi.org/10.3892/ijo_00000316
47. Leick MB, Shoff CJ, Wang EC, Congress JL, Gallicano GI. Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer. Am J Stem Cells 2012; 1:59-74; PMID:23671798
48. Sher F, Boddeke E, Olah M, Copray S. Dynamic changes in Ezh2 gene occupancy underlie its involvement in neural stem cell self-renewal and differentiation towards oligodendrocytes. PLoS One 2012; 7:e40399; PMID:22808153; http://dx.doi.org/10.1371/journal.pone.0040399
49. Wu HA, Bernstein E. Partners in imprinting: noncoding RNA and polycomb group proteins. Dev Cell 2008; 15:637-8; PMID:19000827; http://dx.doi.org/10.1016/j.devcel.2008.10.008
50. Zacharek SJ, Fillmore CM, Lau AN, Gludish DW, Chou A, Ho JW, Zamponi R, Gazit R, Bock C, Jäger N, et al. Lung stem cell self-renewal relies on BMI1- dependent control of expression at imprinted loci. Cell Stem Cell 2011; 9:272-81; PMID:21885022; http://dx.doi.org/10.1016/j.stem.2011.07.007
51. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20:1123-36; PMID:16618801; http://dx.doi.org/10.1101/gad.381706
52. Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N, Amin MB, Carney JK, Marshall FF, Petros JA, et al. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005; 24:188-98; PMID:15637592; http://dx.doi.org/10.1038/sj.onc.1207906
53. Moreno CS. The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. Am J Pathol 2010; 176:518-27; PMID:20019190; http://dx.doi.org/10.2353/ajpath.2010.090657
54. Lei H, Juan AH, Kim MS, Ruddle FH. Identification of a Hoxc8-regulated transcriptional network in mouse embryo fibroblast cells. Proc Natl Acad Sci U S A 2006; 103:10305-9; PMID:16793922; http://dx.doi.org/10.1073/pnas.0603552103
55. Lei H, Wang H, Juan AH, Ruddle FH. The identification of Hoxc8 target genes. Proc Natl Acad Sci U S A 2005; 102:2420-4; PMID:15699330; http://dx.doi.org/10.1073/pnas.0409700102
56. Waltregny D, Alami Y, Clausse N, de Leval J, Castronovo V. Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate 2002; 50:162-9; PMID:11813208; http://dx.doi.org/10.1002/pros.10045
57. Axlund SD, Lambert JR, Nordeen SK. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes. Mol Cancer Res 2010; 8:1643-55; PMID:21047772; http://dx.doi.org/10.1158/1541-7786.MCR-10-0111
58. Ulrix W, Swinnen JV, Heyns W, Verhoeven G. Androgens down-regulate the expression of the human homologue of paternally expressed gene-3 in the prostatic adenocarcinoma cell line LNCaP. Mol Cell Endocrinol 1999; 155:69-76; PMID:10580840; http://dx.doi.org/10.1016/S0303-7207(99)00113-6
59. Gonit M, Zhang J, Salazar Md, Cui H, Shatnawi A, Trumbly R, Ratnam M. Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements. Mol Endocrinol 2011; 25:621-34; PMID:21330406; http://dx.doi.org/10.1210/me.2010-0409
60. Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, Wills ML, Logan SK, Zhang P, Matusik RJ.Down-regulation of p57Kip2 induces prostate cancer in the mouse. Cancer Res 2008; 68:3601-8; PMID:18483241; http://dx.doi.org/10.1158/0008- 5472.CAN-08-0073
61. Schwarze SR, Shi Y, Fu VX, Watson PA, Jarrard DF. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 2001; 20:8184-92; PMID:11781834; http://dx.doi.org/10.1038/sj.onc.1205049
62. Charalambous M, da Rocha ST, Ferguson-Smith AC. Genomic imprinting, growth control and the allocation of nutritional resources: consequences for postnatal life. Curr Opin Endocrinol Diabetes Obes 2007; 14:3-12; PMID:17940412; http://dx.doi.org/10.1097/MED.0b013e328013daa2
63. Hayashida T, Eversole-Cire P, Jones PA, Sasaki H. Imprinted genes are up-regulated by growth arrest in embryonic fibroblasts. J Biochem 1997; 122:901-3; PMID:9443803; http://dx.doi.org/10.1093/oxfordjournals.jbchem.a021850
64. Hornstein M, Hoffmann MJ, Alexa A, Yamanaka M, Müller M, Jung V, Rahnenführer J, Schulz WA. Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics 2008; 5:123-36; PMID:18460741
65. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Buchardt M, Seifert HH, Visakorpi T. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 2002; 35:58-65; PMID:12203790; http://dx.doi.org/10.1002/gcc.10092